Pre-made Infliximab benchmark antibody ( Whole mAb, anti-TNFA/TNF therapeutic antibody, Anti-DIF/TNFSF2/TNLG1F Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Infliximab biosimilar, Whole mAb, Anti-TNFA/TNF Antibody: Anti-DIF/TNFSF2/TNLG1F therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Beh?et’s disease. It is given by slow injection into a vein, typically at six- to eight-week intervals.
| Products Name (INN Index) | Pre-Made Infliximab biosimilar, Whole mAb, Anti-TNFA/TNF Antibody: Anti-DIF/TNFSF2/TNLG1F therapeutic antibody |
|---|---|
| INN Name | Infliximab |
| Target | TNF |
| Format | Whole mAb |
| Derivation | Chimeric (Mouse/Human) |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | NFD |
| 100% SI Structure | 5vh3:HL:AB/5vh4:HL:AB/4g3y:HL/6ugs:HL:AB/6ugv:HL:AB/6ugt:HL:AB/6ugu:HL:AB |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 1997 |
| Year Recommended | 1998 |
| Companies | Centocor,Janssen Biotech,Merck & Co,Mitsubishi Tanabe Pharma Corporation,National Jewish Medical and Research Center,Xian-Janssen |
| Conditions Approved | Ankylosing spondylitis,Behcet's syndrome,Crohn's disease,Mucocutaneous lymph node syndrome,Plaque psoriasis,Psoriasis,Psoriatic arthritis,Rheumatoid arthritis,Ulcerative colitis |
| Conditions Active | NA |
| Conditions Discontinued | Berylliosis,Hepatitis C,Pyoderma |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | TNFA |
| Package |
